What Men Get Wrong About Prostate Health Screenings

Prostate cancer is often described as a "silent" disease in its early stages. Waiting for urinary difficulty, pain, or other warning signs before discussing screening means the cancer may already be more advanced. The entire point of screening is to detect changes before symptoms develop — which is why the absence of symptoms is not a green light to skip the conversation with your doctor.

PSA is a protein produced by both normal and abnormal prostate tissue. Levels can rise due to benign prostatic hyperplasia (BPH), prostatitis (prostate inflammation or infection), recent ejaculation, vigorous cycling, or even a digital rectal exam performed shortly before the blood draw. An elevated result triggers further evaluation — it is not a diagnosis. Understanding BPH and its relationship to PSA is useful background; see our article on BPH and when symptoms warrant medical review.

Men with a first-degree relative (father or brother) diagnosed with prostate cancer before age 65, as well as Black men — who face a higher statistical risk of prostate cancer — are generally advised to begin the screening conversation earlier, often around age 40 to 45. Guidelines from the American Cancer Society and other bodies emphasize individualized risk assessment rather than a single universal age. For a broader picture of age-based screening timelines, see what gets checked and at what age.

The U.S. Preventive Services Task Force (USPSTF) recommends that men aged 55 to 69 make an individualized decision about PSA screening in consultation with their clinician, weighing potential benefits against risks such as false positives and overtreatment. There is no single blanket recommendation to screen all men. This is why an informed conversation — rather than an automatic annual test — is the standard approach for most men in the relevant age range.

Fear of treatment side effects — including incontinence or erectile dysfunction — leads some men to avoid screening entirely. While those side effects are real risks for certain treatments, many low-risk prostate cancers are managed through active surveillance: close monitoring without immediate surgery or radiation. Modern treatment approaches are more nuanced than they were decades ago, and the decision about how to proceed depends heavily on the cancer's grade, stage, and the individual's overall health and preferences.